Abstract
The cytotoxic activity of peripheral mononuclear cells (PMNC) from patients with acute myelogenous leukemia (AML) is usually reduced at time of diagnosis [1, 2]. Production and release of immunosuppressive cytokines by leukemic blast cells might be a cause for impaired cytotoxic activity and immunosurveillance of leukemic cells. Indeed, soluble but yet undefined factors secreted by AML blasts have been described to be reponsible for inhibited cytotoxic activity in AML patients [3, 4]. Transforming growth factor beta (TGF-β) has been reported to be a strong inhibitor of cytotoxic activity of lymphokine activated killer (LAK) cells [5–9]. In ovarian carcinoma, increased TGF-β secretion was shown to suppress various immune functions [10]. It may be suggested that TGF-β may be an important factor in AML, too, causing immunosuppression.KeywordsAcute Myeloid LeukemiaAcute Myelogenous LeukemiaLymphokine Activate KillerLymphokine Activate Killer CellAcute Leukemia PatientThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
